Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF) is a leader in biofilm-disrupting technologies for advanced wound and scalp care. This page aggregates all official company announcements, providing stakeholders with timely updates on regulatory progress, product developments, and strategic initiatives.
Investors and industry professionals will find comprehensive coverage of FDA clearances, manufacturing partnerships, and global licensing agreements. Our curated news stream includes earnings reports, clinical advancements, and distribution expansions, ensuring you never miss critical developments affecting KNBIF's market position.
Key focus areas include updates about antimicrobial wound care solutions, scalp health innovations, and quality certifications like ISO 13485:2016. Bookmark this page for direct access to primary-source information about Kane Biotech's progress in combating biofilm-related health challenges worldwide.
Kane Biotech Inc. (OTCQB: KNBIF) announced a new credit agreement with Pivot Financial, increasing its credit facility from $1.48 million to $2.5 million. The funds will support research and development, cover expenses related to STEM Animal Health Inc., and provide working capital. CFO Ray Dupuis emphasized that this facility enhances the company's liquidity during ongoing partnership discussions. Pivot Financial's President, Dan Flaro, noted the improved terms, which facilitate the commercialization of Kane Biotech's intellectual property, comprising 52 patents and trademarks.
Kane Biotech Inc. has announced the shipment of its first order of bluestem™ oral care products to PetSmart Canada. These products will be available in all 150 PetSmart stores and online, aimed at improving pet oral health by combating harmful biofilms like plaque and tartar.
Developed by STEM Animal Health Inc., a joint venture between Kane Biotech and Animalcare Group PLC, bluestem™ utilizes coactiv+™ technology to effectively reduce tartar without harsh chemicals. Kane Biotech is traded under the symbols KNE on TSX and KNBIF on OTCQB.
Kane Biotech (KNBIF) reported its Q2 2021 results, showcasing a revenue increase to $278,741, up from $267,493 in Q2 2020. However, gross profit fell to $83,584 compared to $115,570 in the previous year, while operating expenses surged to $1,090,396 from $711,448. This led to a loss from operations of ($1,006,812), compared to ($595,878) in Q2 2020. The CEO expressed optimism about growth in animal health, OTC/dermatology, and wound care, and highlighted recent patent grants and new partnerships. The company has also raised $1,116,000 in warrant exercises this year.
Kane Biotech is set to announce its Q2 2021 financial results on August 26, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss these results and recent business developments. The company focuses on technologies aimed at preventing and removing microbial biofilms and boasts a solid portfolio with 54 patents. Kane Biotech operates under the stock symbols KNE on TSX Venture and KNBIF on OTCQB.
Kane Biotech has received two Decisions to Grant from the European Patent Office for its coactiv+™ technology, enhancing patent coverage for its wound and skin infection treatments. The granted patents cover proprietary formulations, expanding the scope and term of protection significantly. CEO Marc Edwards emphasized the technology's versatility across various applications, including personal care and wound healing. The coactiv+™ technology destabilizes biofilms to promote healing and is recognized as safe by the FDA, positioning Kane for commercialization opportunities.
Kane Biotech Inc. is expanding its wound care portfolio with a new antimicrobial hydrogel utilizing its coactiv+™ technology, aiming for quicker market access via the 510(k) regulatory pathway. The US market for wound care hydrogels is estimated at US$200M. This initiative aligns with Kane's strategy to leverage its biofilm research and intellectual property for developing treatments for biofilm-related infections.
Laboratory tests suggest coactiv+™ effectively inhibits bacterial biofilm formation, making it a promising addition to wound healing products.
Kane Biotech has announced the cancellation of 8,470,555 stock options held by directors, officers, and employees, while simultaneously issuing 10,739,488 restricted share units (RSUs). These RSUs can be converted into common shares over a ten-year period following their grant. This action is part of the company's performance and restricted share unit plan dated April 21, 2021. Kane Biotech focuses on developing technologies to combat microbial biofilms and holds 54 patents and pending patents.
Kane Biotech Inc. has developed a new stable topical hydrogel formulation of DispersinB® for wound care, marking a significant milestone in its product development. The company partnered with Dow Development Laboratories for clinical manufacturing, planning a randomized study in 2022 to assess safety and efficacy on chronic wounds. This initiative is backed by financial support from Western Economic Diversification Canada and MTEC. DispersinB® targets biofilm, a major barrier to wound healing, potentially revolutionizing treatment for resistant infections.
Kane Biotech Inc. is set to enhance its investor relations at the 10th Annual Whistler 2021 Capital Conference from July 9-11, 2021. CEO Marc Edwards will meet investors to discuss progress in animal health, OTC consumer goods, and wound care. Key highlights include:
- $2.7 million funding from the US Department of Defense for DispersinB® development.
- Growing partnerships in pet oral care, targeting a $5 billion market.
- 6.2 million warrants exercised, providing crucial cash for investments.
For further details, visit kanebiotech.com.
Kane Biotech has launched a five-part video series titled “2021 Business Update”, starting with Episode 1 - “The Fundamentals”, released on June 16, 2021. This series aims to inform stakeholders about the company's strategies across its three key areas: OTC consumer products, animal health, and wound care. The first episode includes insights from CEO Marc Edwards and Chief Scientific Officer Gordon Guay, focusing on market opportunities and the company's approach to addressing biofilm-related issues. Subsequent episodes will cover innovations in various product lines and funding strategies.
